Protocol Ledger

NCT05067790 · Phase III · ACTIVE NOT RECRUITING

A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND)

Interventional Phase III clinical trial protocol NCT05067790 sponsored by Biogen in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-01-21 Enrollment: 45 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05067790
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)45 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05067790
Protocol FieldVerified Registry Value
NCT IdentifierNCT05067790
Consolidated Lead SponsorBiogen
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment45 participants (ACTUAL)
Registered Start Date2022-01-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Biogen across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI